Acambis Plc Announces Results for the First Quarter Ended 31 March 2006 (SYS-CON Media)
Results for the first quarter ended 31 March 2006

Cytogen Announces FDA Clears IND For CYT-500, A Monoclonal Antibody For The Treatment Of Metastatic Hormone-Refractory (Medical News Today)
Cytogen Corporation(Nasdaq: CYTO) announced today the U.S. Food and Drug Administration (FDA)has cleared an Investigational New Drug (IND) application for CYT-500, thecompany's lead therapeutic candidate targeting prostate-specific membraneantigen (PSMA). Cytogen expects to begin the first U... click link for more info.

Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory (PR Newswire via Yahoo! Finance)
Cytogen Corporation announced today the U.S. Food and Drug Administration has cleared an Investigational New Drug application for CYT-500, the company's lead therapeutic candidate targeting prostate-specific membrane antigen .